Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $10.60 on Friday. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The stock has a 50-day moving average of $11.11 and a two-hundred day moving average of $10.64. The stock has a market cap of $3.14 billion, a P/E ratio of -21.63 and a beta of 0.69. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same period last year, the business posted ($0.15) earnings per share. As a group, research analysts predict that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Institutional Trading of Amicus Therapeutics

Several large investors have recently made changes to their positions in the business. Headlands Technologies LLC purchased a new position in shares of Amicus Therapeutics during the second quarter worth $89,000. Sage Capital Advisors llc purchased a new stake in Amicus Therapeutics in the second quarter valued at $103,000. Old Well Partners LLC acquired a new stake in Amicus Therapeutics during the 4th quarter worth about $180,000. EntryPoint Capital LLC raised its stake in shares of Amicus Therapeutics by 278.8% during the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 9,729 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Amicus Therapeutics in the 2nd quarter valued at about $138,000.

Analyst Ratings Changes

Several research firms have issued reports on FOLD. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a report on Friday, September 20th. Jefferies Financial Group began coverage on Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. decreased their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $17.00.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.